Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs)
Aurore VozyAudrey SimonaggioÉdouard AuclinLaura MezquitaCapucine BaldiniPatricia Martín-RomanoBarbara PistilliAnas GazzahRastilav BahledaVincent RibragSophie Postel‐VinayStéphane ChampiatJean‐Charles SoriaFabrice AndréChristophe MassardBenjamin BesseSuzette DelalogeAndréa Varga
6
Citation
0
Reference
10
Related Paper
Citation Trend
Keywords:
Clinical endpoint
Triple-negative breast cancer
Triple negative breast cancer (TNBC) is a special type of breast cancer.Its special clinical pathological characteristic and molecule expression type make the treatment of TNBC become an international problem.In recent years,a variety of attempts and explorations to the treatment of TNBC have made some initial results,which provides a direction for the treatment of TNBC and offers hope for the patients with TNBC.
Key words:
Breast neoplasms; Combined modality therapy; Triple-negative
Triple-negative breast cancer
Triple negative
Modality (human–computer interaction)
Cite
Citations (0)
Abstract Abstract #5121 Purpose: It is said that triple negative breast cancer (TNBC) has poor prognosis. However, many study shows TNBC has better response to chemotherapy. Since neoadjuvant chemotherapy plays an important role to TNBC, we compared clinical and pathological response rate and prognosis between TNBC and non-TNBC.
 Patients and methods: This analysis retrospectively collected 2563 breast cancer patients for StageI-III who underwent surgery between January 2000 and September 2004 (median: 3.9 years) at National Cancer Center, Tokyo, Japan. We defined TNBC as Estorpgen and progesterone receptor negative and HER2 score 0-2+ by immnohistological report. There were 91 TNBC patients (23.1%) out of 400 patients (15.6%) who underwent neoadjuvant chemotherapy. Clinical and pathological response rate and Four-year progression free survival were compared between TNBC and non-TNBC.
 Results: There were 91 TNBC patients (23.1%). TNBC patients compared with non-TNBC had tendency to achieve cCR (91% vs 78%; p=.058) although TNBC had higher rate for cPD (6.6% vs 1.7%; p <.0001). Also TNBC tended to have higher pathological CR rate of which we classified pCR only for grade 3 cases, compared to non-TNBC (13.1% vs 7.2%; p= .042 ). Interestingly HER2 overexpression type also had higher rate for pCR. As for pPD rate, TNBC had similar rate compared to non-TNBC (5.5% v 4.3%). Four-year progression free- survival rate was higher for non-TNBC. However, TNBC had higher Four-year survival free rate only when pCR were achieved after neoadjuvant chemotherapy (99% vs 82%; p=.02).
 Conclusion: Patients with TNBC tend to have clinical and pathological response of either CR or PD. Although non-TNBC had better prognosis by four-year survival free rate, TNBC could have better prognosis if neoadjuvant chemotherapy resulted in pCR. There may be some way to predict the efficacy of neoadjuvant chemotherapy and prognosis by analyzing the shrink pattern. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5121.
Triple-negative breast cancer
Neoadjuvant Therapy
Cite
Citations (1)
BACKGROUNDTriple-negative breast cancer patients have no expression of Oestrogen Receptor (ER), Progesterone Receptor (PR) and there is neither expression nor amplification of human epidermal growth factor receptor 2 in a tumour.But non-triple negative breast cancer patients have either oestrogen receptor or progesterone receptor or both positive with or without amplification of Human epidermal growth factor receptor 2 in a tumour.The purpose of this retrospective study is to compare and analyse the clinico-pathological features, recurrence, metastasis and prognosis of triple-negative breast cancer patients and non-triple negative breast cancer patients. MATERIALS AND METHODSA retrospective descriptive study for a total of 200 stage III female breast cancer patients (100 triple-negative patients and 100 non-triple-negative patients) were diagnosed and treated at the Department of Radiotherapy, T.D Medical College Hospital, Alappuzha from January 1 st 2011 to December 31 st 2011.The clinical features, recurrence, metastasis and prognosis of the two groups were compared. RESULTSThe triple-negative breast cancer patients were characterised as younger age, higher histological grade, bigger tumour size, higher clinical stage at diagnosis, more recurrence and metastasis, lower 5-year disease free survival rate and 5-year overall survival rate.The lungs, liver and brain were the first three most common sites of metastases. CONCLUSIONIn our study, we found that triple-negative breast cancer was a distinct subgroup of breast cancer with particular clinico-pathologic behaviour.Compared with the non-triple-negative breast cancer, triple-negative breast cancer was characterised by more aggressive behaviour, metastasis tendency and lower disease-free survival and overall survival rate.This result suggested that characteristics like family history, premenopausal status, tumour size, histological grade of triple-negative breast cancer patients had more local relapse and metastases than that of in non-triple-negative breast cancer that was statistically significant.
Triple-negative breast cancer
Triple negative
Cite
Citations (0)
Triple-negative breast cancer
Cite
Citations (142)
Triple-negative breast cancer
Triple negative
Cite
Citations (0)
Abstract The heterogeneity of triple negative breast cancer (TNBC) is reflected in a bizarre response to therapy. Although it is chemotherapy sensitive, the failure is the usual pathway either in local or distance status. With progression in Gene Expression Profile (GEP) and other molecular techniques, TNBC is divided into sub-types with unique pathways. In the current review, we are trying to highlight based on the molecular classification of TNBC and the management based on every type.
Triple-negative breast cancer
Triple negative
Cite
Citations (0)
Abstract Introduction Triple negative breast cancer is a heterogeneous disease with no established targeted treatment options for patients with metastatic disease. Methods A cohort of 5500 patient samples was evaluated for differences and similarities in gene mutation (Sanger or Illumina Truseq), protein expression (immunohistochemistry), and/or amplification/rearrangement (CISH or FISH) between triple negative and non-triple negative breast cancers, with 16% of those patients identified as triple negative by IHC testing. Results PIK3CA and P53 gene mutations, PIK3CA, TOP2A, and EGFR amplification (measured as ≥ 4 copies in 40% or more tumor cells by FISH), and AR, EGFR, SPARC, and TS protein expression were shown to differ between the triple negative and non-triple negative breast cancer patients. The rate of mutation of the P53 tumor suppressor gene, measured by sequencing was twice as high in TNBC patients as in non-TNBC patients (60% versus 30%), while PIK3CA was mutated in half as many TNBC patients (12% versus 31% of non-TNBC patients). Amplification of Her2, PIK3CA, cMYC, and TOP2A was significantly greater in the non-TNBC patient population, while amplification of EGFR was significantly higher in the TNBC patient population (24% versus 13% of non-TNBC patients). Androgen receptor was expressed in 56% of the non-TNBC cohort but in only 15% of the TNBC cohort. Conclusions The gene mutation and protein expression differences in the triple negative subset of breast cancer patients, such as EGFR amplification, SPARC protein expression and P53 gene mutation, could inform new therapeutic possibilities for these difficult to treat, often more aggressive cancers. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD4-1.
Triple-negative breast cancer
CISH
Sanger sequencing
Cite
Citations (1)
Triple-negative breast cancer (TNBC) is known to have unique molecular, clinical, and pathologic characteristics. The growth pattern of this cancer may also affect its appearance on sonography. Our study evaluated the sonographic features of TNBC according to the American College of Radiology Breast Imaging Reporting and Data System sonographic classification system and compared these features with those of non-TNBC.Data from 315 consecutive breast cancer cases were collected. The images were reevaluated by an examiner blinded to the patients' characteristics and histologic results according to the Breast Imaging Reporting and Data System. The sonographic features of TNBC (n = 33) and non-TNBC (n = 282) were compared.Triple-negative breast cancer was significantly correlated with a younger patient age (P = .002) and was associated with higher tumor grades (P < .001), more lymph node involvement (P = .014), and a trend toward a larger tumor size. With regard to sonographic features, the margin of TNBC was more frequently described as lobulated or microlobulated (75.8% versus 49.5% in non-TNBC; P = .005). The echoic halo was observed significantly less often in TNBC than in non-TNBC(39.4% versus 62.8%; P = .014). Cooper ligaments were displaced rather than disrupted in TNBC compared to non-TNBC (P = .003). Regarding the posterior acoustic features, enhancement was observed significantly more often in TNBC (36.4% versus 13.0% in non-TNBC; P = .031).Triple-negative breast cancer and non-TNBC have different sonographic features. This finding can be explained by the pathologic profile of this breast cancer subtype. Some of the distinct sonographic criteria for TNBC are more likely to be associated with benign masses. Knowledge of the distinct sonographic features of TNBC would help the examiner avoid false-negative classification of this tumor type.
Triple-negative breast cancer
Triple test
Cite
Citations (78)
Triple-negative breast cancer
Triple negative
Triple test
Cite
Citations (0)
Triple-negative breast cancer
Triple junction
Triple negative
Cite
Citations (0)